Novo Nordisk’s Wegovy has received FDA approval for an additional indication targeting noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2 to F3 fibrosis stages), in conjunction with a reduced calorie diet and increased physical activity. This approval was granted based on the positive results from the ESSENCE trial’s first part, where Wegovy showcased significant improvement in liver fibrosis without worsening steatohepatitis, alongside resolution of steatohepatitis without exacerbating liver fibrosis compared to a placebo group.
The ESSENCE trial data at week 72 revealed that 36.8% of individuals treated with Wegovy experienced enhanced liver fibrosis without exacerbating steatohepatitis, compared to 22.4% in the placebo cohort. Furthermore, 62.9% of Wegovy-treated participants achieved resolution of steatohepatitis without worsening liver fibrosis, compared to 34.3% in the placebo arm. Novo Nordisk’s ongoing efforts include the second part of the ESSENCE trial, aiming to demonstrate a reduction in liver-related clinical events with semaglutide 2.4 mg compared to a placebo over 240 weeks, with results expected in 2029.
This approval signifies a significant milestone for Novo Nordisk amidst declining sales of its GLP-1 products in Europe due to slow market penetration and continued use of compounded alternatives. The company projects a sales growth range of 8-14% by 2025 at constant exchange rates, a revision from its previous forecast of 13-21%. Additionally, Health Canada is reviewing Novo Nordisk’s submission for semaglutide 2.4 mg as a weekly therapy for MASH under its Priority Review policy, reflecting the company’s commitment to expanding Wegovy’s indications.
In March 2024, the FDA expanded Wegovy’s label based on another supplemental application, which aimed to reduce major adverse cardiovascular events (MACE) in adults with overweight or obesity and established cardiovascular disease. The SELECT trial demonstrated a 20% reduction in MACE risk with Wegovy compared to a placebo, with sustained risk reductions over five years. Furthermore, data from SELECT showcased a 15% decrease in cardiovascular death risk and a 19% decrease in all-cause mortality compared to placebo, reinforcing Wegovy’s cardiovascular benefits.
Novo Nordisk’s success with Wegovy’s expanded indications aligns with its strategic growth objectives and commitment to addressing unmet medical needs. The company’s proactive approach to seeking regulatory approvals and conducting robust clinical trials underscores its dedication to advancing innovative therapies for complex diseases like MASH and cardiovascular conditions. With ongoing trials and regulatory submissions, Novo Nordisk is poised to solidify Wegovy’s position as a pivotal treatment option for patients with diverse metabolic and liver-related disorders.
Key Takeaways:
– Novo Nordisk’s Wegovy secures FDA approval for treating MASH in adults with liver fibrosis, showcasing significant clinical benefits compared to a placebo.
– The company’s strategic focus on expanding Wegovy’s indications aligns with its growth projections and commitment to addressing unmet medical needs.
– Ongoing clinical trials and regulatory submissions underscore Novo Nordisk’s dedication to advancing innovative therapies for metabolic disorders and cardiovascular diseases.
Read more on aol.com